Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKaspire: Belumosudil in Chronic Lung Allograft Dysfunction
NCT06082037Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2023
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in chronic lung allograft dysfunction (CLAD) comparing Belumosudil + Azithromycin with Placebo + Azithromycin (2 arms). Primary endpoint: Percent change in forced expiratory volume in 1 second at 26 weeks. Started Oct 2023; status: recruiting.
02
Drugs
belumosudil
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on NCT06082037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082037.